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S328 Poster Session IIunrelated donors [9/10HR5 9 (4-20), p\0.001; 10/10HR5 4 (1.2-
10), p 5 0.03], female donors [HR 5 3 (1.2-7); p 5 0.01] and ABO
minor incompatibility [HR5 2.5 (1.2-5), p5 0.01].We showed that
allo-HSCTfrom9/10HLAmismatchedunrelated donors have a sig-
nificantly worse OS than those from matched unrelated donors and
siblings; this was mainly due to an increased TRM in this group. Pa-
tients in first CR or CP could benefit themore frommatched or 9/10
unrelated allo-HSCT while the use of transplants from 9/10 HLA
unrelated donors in patients not in CR1 should be limited to clinical
trials.
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Introduction: A small minority of patients (pts) with AcuteMyeloid
Leukemia (AML) achieve complete remission (CR3) after a second
relapse. The role of allogeneic HCT (allo-HCT) for such patients
is unclear. Here we present the outcomes of CR3 AML patients
treated at the M D Anderson Cancer Center.
Methods: We conducted a retrospective analysis of prospectively
collected data on all AML pts (n 5 33) who received their allo-
HCT in $ CR3 between 11/2/1990- 7/1/2009.
Results:Median age was 40 years (range, 19-67) and 46% were fe-
male. CR3 pts comprised 2.7% of all pts with AML treated at the
same time period in our institution (n 5 1227). 3/33 had secondary
AML (2 with prior myelodysplastic syndrome and one with previ-
ous myeloproliferative disorder). Cytogenetics risk categories were
low in 24%, intermediate in 30%, high in 21% and unknown in
25%. Pts had a median of 4 chemotherapy lines prior to transplant.
Donor was matched unrelated in 48%, matched related in 24%,
mismatched related in 15% and mismatched unrelated 9%. Graft
source was peripheral blood (52%), marrow (39%) or umbilical
cord blood (9%). Ten pts had prior allo-HCT. Conditioning reg-
imen was of reduced intensity in 60% and myeloablative in 40% of
pts. and 84% of pts received Tacrolimus/Methotrexate +/- Pentos-
tatin for graft- versus-host disease (GVHD) prophylaxis. 97% of
the pts engrafted. Cumulative incidence rate of grade II-IV acute
GVHD was 26% and of chronic GVHD was 27%. Overall survival
was 19% (95 % CI: 7-34%) and progression-free survival (PFS)
was 12% (95% CI: 3-26%)[Figure below]. Relapse rate was 29%,
and cumulative incidence of non relapse mortality (NRM) was
46%. Less NRM was seen among pts who had allo-HCT after
year 2002, year in which molecular class I HLA typing was incor-
porated (32% vs. 64%; p 5 0.9); improved PFS was also observed
after 2002 (22% vs. 0% before 2002, p 5 0.5). Prior allo-HCT was
not a risk factor for adverse outcomes with PFS of 20% with prior
HCT vs. 7% for pts without prior allo-HCT (p 5 0.7) and NRM
rates were comparable (20% vs. 58%; p 5 0.3). Seven pts are alive,
with a median follow-up of 11.3 months. Causes of death (n 5 26)
were relapse (n 5 7), infections (n 5 8), GVHD (n 5 5), other (n 5
3), and unknown (n 5 3).
Conclusions: Pts in CR3may benefit from allo-HCT, but should be
considered for investigational approaches given high non-relapse
and relapse mortality.
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Although allogeneic transplant remains a potent immunotherapy
for high-risk hematopoetic malignancies, relapse is the main cause
of treatment failure. We, and others, have shown that alloreactivity
associated with minor histocompatibility antigen (miHA) mismatchreduces quantitative responses to vaccines targeting tumor-specific
antigens. The effect of miHA mismatch on the antitumor response
when the tumor also expresses the miHA has not been well-studied,
and could provide important insight into the biology of the graft-ver-
sus-tumor effect. We therefore utilized a murine allotransplant sys-
tem in which donors and recipients weremismatched at the clinically
relevant male miHA HY, followed by DLI with HY-specific T cells
and challenge with an HY-expressing tumor. Professional HY anti-
gen presentation was provided at the time of DLI using an activated
male dendritic cell (DC) vaccine. Recipients were monitored for
clinical GVHD and antitumor responses measured by tumor-free
and overall survival. Further analysis of HY specific T-cells in sec-
ondary lymphoid organs was performed by flow cytometry using
congenic markers.WhenHY is expressed only on the tumor, follow-
ing syngeneic transplant of female (HY-naive) T-cell depleted mar-
row into female recipients, there is 100% tumor-free survival
following HY-specific DLI and male vaccination. However, when
HY is expressed in all nonhematopoetic tissues, following transplan-
tation of female marrow into male recipients, there is approximately
20% tumor-free survival regardless of whether an activatedmale DC
vaccine is given. Interestingly, expression of HY in both the non-
hematopoetic and hematopoetic (when male marrow is transplanted
into female recipients) compartments produces a robust expansion of
HY-specific T-cells, suggesting that the impaired antitumor immu-
nity is due to dysfunction, rather than clonal deletion. Indeed, nearly
100% of HY-specific T-cells from secondary lymphoid organs ex-
press high levels of PD-1 in the allogeneic transplant setting, com-
pared to low levels in syngeneic recipients and no expression in
lymphocytes reconstituted independently of the DLI. Studies are
underway to functionally characterize these exhausted alloreactive
T cells and and identify targets for therapeutic blockade to restore
the effectiveness of antitumor vaccination in the allotransplant set-
ting while minimizing GVHD.335
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Background: It is estimated that over 2,000,000 people suffer from
hepatitis C virus (HCV) infection in Japan. Therefore, HCV infec-
tion is one of major liver diseases. In hematopoietic stem cell trans-
plantation (HSCT), HCV infections of recipients might induce
a transient liver dysfunction, and an increasing risk of veno-occlusive
disease (VOD), although these are controversial. In addition, the ge-
notypes of HCV in Japan are considered different from those in
Western countries. Therefore, we have assessed the impact of
HCV sero-positivity of recipients on clinical outcomes in Japan.
Patients: The population was based on TRUMP data confirmed in
2010. The eligible population included the all recipients who re-
ceived an initial allogeneic HSCT since 2006 and whose data about
age, gender, HCV sero-positivity of recipients and status of survival
at last observation were available.
Results: We identified 136 and 7720 recipients with and without
HCV, respectively. Although more recipients with HCV tended
to be male (p 5 0.054) and to receive female to male HSCT
(p 5 0.081), there were no differences in other background. The
recovery of more than 5x10^10/L platelet was significantly later
in recipients with HCV (38 vs 47 days, p 5 0.013), while there
was no significant difference in neutrophil engraftment. There
were no differences between groups without and with HCV in
